Cancer Institute A national cancer institute
designated cancer center

Matthew Bogyo

Publication Details

  • Cathepsin V, a novel and potent elastolytic activity expressed in activated macrophages JOURNAL OF BIOLOGICAL CHEMISTRY Yasuda, Y., Li, Z. Q., Greenbaum, D., Bogyo, M., Weber, E., Bromme, D. 2004; 279 (35): 36761-36770

    Abstract:

    Atherosclerosis is characterized by a thickening and loss of elasticity of the arterial wall. Loss of elasticity has been attributed to the degradation of the arterial elastin matrix. Cathepsins K and S are papain-like cysteine proteases with known elastolytic activities, and both enzymes have been identified in macrophages present in plaque areas of diseased blood vessels. Here we demonstrate that macrophages express a third elastolytic cysteine protease, cathepsin V, which exhibits the most potent elastase activity yet described among human proteases and that cathepsin V is present in atherosclerotic plaque specimens. Approximately 60% of the total elastolytic activity of macrophages can be attributed to cysteine proteases with cathepsins V, K, and S contributing equally. From this 60%, two-thirds occur extracellularly and one-third intracellularly with the latter credited to cathepsin V. Ubiquitously expressed glycosaminoglycans (GAGs) such as chondroitin sulfate specifically inhibit the elastolytic activities of cathepsins V and K via the formation of specific cathepsin-GAG complexes. In contrast, cathepsin S, which does not form complexes with chondroitin sulfate is not inhibited; thus suggesting a specific regulation of elastolytic activities of cathepsins by GAGs. Because the GAG content is reduced in atherosclerotic plaques, an increase of cathepsins V and K activities may accelerate the destruction of the elastin matrix in diseased arteries.

    View details for DOI 10.1074/jbc.M403986200

    View details for Web of Science ID 000223453600077

    View details for PubMedID 15192101

Stanford Medicine Resources:

Footer Links: